PPARA and metabolic dysfunction-associated steatohepatitis: In contrast, elafibranor, a high-affinity agonist for PPAR-α/δ, exerts its effect on NASH amelioration mainly by increasing clearance of fatty acids, as well as inhibition of pathways involved in inflammation and fibrosis [26, 33, 34].